Aug 23, 2014
Posted by Seb in categories: biotech/medical, robotics/AI
Ariel Schwartz — Fast Company
BPM 31510 is just another cancer drug in human development trials, except for one thing. Scientists didn’t toil away in labs to come up with it; artificial intelligence did.
The cancer drug development process is costly and time-consuming. On average, it takes 24 to 48 months and upwards of $100 million to find a suitable candidate. Add that to the fact that 95% of all potential drugs fail in clinical trials, and the inefficiencies of the whole drug-discovery machine really become apparent.
Backed by real estate billionaire Carl Berg, eponymous biotech startup Berg wants to use artificial intelligence to design cancer drugs that are cheaper, have fewer side effects, and can be developed in half the time it normally takes. BPM 31510 is the first of Berg’s drugs to get a real-world test.